BIOTRONIK, a global leader in cardio- and endovascular medical technology products that is headquartered in Berlin, Germany announced on thursday that its new center in Singapore has begun operations. This expands the company’s existing hubs in Europe and the United States, and positions manufacturing close to growing Asia Pacific markets.
BIOTRONIK has been a pioneer in implantable pacemakers, defibrillators and stent therapy for over 50 years, and has achieved double-digit revenue growth over the last decades. Its Asia Pacific headquarters have been located in Singapore since 2012.
The new site includes a 1500 m² ISO class 7 cleanroom, supplying the global market with products for the company’s vascular intervention and cardiac rhythm management businesses. It produces Orsiro, the world’s first hybrid drug-eluting coronary stent, along with Solia pacemaker leads.
“Singapore’s skilled workforce, excellent infrastructure and favorable business environment made it a natural choice for BIOTRONIK as we seek to expand our global footprint,” said Erik Trip, Managing Director, Asia Pacific Manufacturing, BIOTRONIK.
“We are building a professional team at the new site and will eventually create hundreds of new jobs in this exciting industry. This investment will support BIOTRONIK’s dynamic growth, both in the Asia Pacific region and globally.”
The company plans to create over 200 jobs for highly-trained operators and professionals in R&D and senior leadership roles, investing more than 30 million Singapore dollars (20 million euros) into operations in the country over the next few years.
“We welcome BIOTRONIK’s decision to establish its Asia Pacific manufacturing facility in Singapore. This is testament to our strong manufacturing workforce, high quality standards, and deep science and engineering capabilities, which are important in the production of implantable cardiovascular devices,” said Weng Si Ho, Director, Biomedical Sciences, Singapore Economic Development Board (EDB).
“Asia continues to provide an exciting growth opportunity for global medical device companies. We are confident that Singapore will continue to grow as a global medical technology hub, which will enable further economic growth and good jobs created here.”